<DOC>
	<DOCNO>NCT00220779</DOCNO>
	<brief_summary>The trial study 2 dos Immune Globulin Intravenous ( Human ) , 10 % Caprylate/Chromatography Purified ( IGIV-C ) number relapse occur 1 year treatment period .</brief_summary>
	<brief_title>Immune Globulin Intravenous ( IGIV ) To Treat Relapsing , Remitting Multiple Sclerosis</brief_title>
	<detailed_description>This trial design multi-national , randomize , double-blind , placebo-controlled prospective trial three parallel group . One hundred twenty ( 120 ) patient , 40 per treatment arm , relapsing-remitting ( RR ) multiple sclerosis enrol trial . Eligible patient must diagnosis MS per McDonald Criteria . In addition , patient must diagnosis relapsing-remitting course MS define period worsen neurological function full recovery sequelae residual deficit upon recovery ; period disease relapse characterize lack disease progression . Patients must also active disease least 1 define document relapse last year . During 2 month run-in period , 2 MRIs perform 6 week apart patient stratify base presence absence 1 Gadolinium enhance lesion first MRI ( Gd-enhancing lesion yes-no ) randomize one two dose regimen IGIV-C matching placebo . Patients receive study drug infusion every 4 week 48 week total 12 infusion . Patients evaluate MRI every 6 week clinical assessment every 3 month . A follow-up visit occur 4 week last infusion . The treatment group follow : - IGIV-C - 0.2 g/kg body weight ( bw ) /infusion ( 2 ml/kg bw ) - IGIV-C - 0.4 g/kg bw/infusion ( 4 ml/kg bw ) - placebo ( 0.1 % albumin ) - 4 ml/kg bw/infusion For blind purpose , infusion , patient receive total volume 4 ml/kg bw . For patient receive 0.2 g/kg bw IGIV-C , final volume 4 ml/kg bw adjust addition dextrose 5 % . Placebo supply Albumin 5 % Albumin 25 % dilute either dextrose 5 % saline final concentration 0.1 % albumin . Dose adaptation perform subsequent infusion case patient 's body weight change &gt; 10 % . The maximum amount available per infusion 400 ml ( 8 vial ) calculate patient body weight 100 kg . The suggested initial infusion rate 0.02 ml/kg/min first 15 minute . If evidence hypersensitivity reaction , infusion may give slowly increase rate next 30 minute maximum allowable rate 0.08 ml/kg/min . As , infusion 70 kg patient take approximately 1hour 15 min . The overall infusion time may range 1 2 hour .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Symptoms consistent Multiple Sclerosis 5 year Diagnosis multiple sclerosis accord McDonald criterion . Diagnosis relapsingremitting ( RR ) multiple sclerosis ( MS ) ( Defined period worsen neurological function full recovery sequelae residual deficit upon recovery ; period disease relapse characterize lack disease progression Kurtzke Extended Disability Status Scale ( EDSS ) &lt; 5.0 At least 1 define document relapse last year . Prior relapse symptom due solely change Bowel/Bladder Function Cognitive Function consider relapse define protocol therefore counted inclusion study . Females male ; female childbearing potential must use adequate contraception Clinically stable least 30 day prior entry At least 9 hyperintense T2 lesion MRI 1 Gdenhancing lesion accord McDonald/Barkhof disseminationinspace criterion entry Patients inform available treatment decide , go treatment Written inform consent obtain prior initiation study relate procedure Females pregnant , breast feeding , , childbearing potential , unwilling practice adequate contraception throughout study Prior therapy azathioprine immunosuppressant agent within 6 month prior study entry Prior steroid , methylprednisolone adrenocorticotropic hormone ( ACTH ) therapy within 30 day prior study entry Therapy interferon ( Betaseron® , Avonex® , Rebif® ) , glatiramer acetate ( Copaxone® ) IGIV within 3 month prior study entry study Use investigational compound within 6 month prior study entry Previous lymphoid irradiation prior treatment cyclophosphamide , methotrexate mitoxantrone Cardiac insufficiency ( NYHA III/IV ) , cardiomyopathy , significant cardiac dysrhythmia require treatment , unstable advanced ischemic heart disease ( CCS III IV ) , malignant hypertension History renal insufficiency serum creatinine level great 2.5 mg/dL ( 221 µmol/L ) Known selective immunoglobulin A ( IgA ) deficiency know antibody IgA Conditions whose symptom effect could alter protein catabolism and/or immunoglobulin G ( IgG ) utilization ( e.g. , proteinlosing enteropathy , nephrotic syndrome ) Any medical , psychiatric circumstance impede restrict patient 's participation study contraindication contrast enhance MRI ( e.g. , pacemaker , aortic clip metal implant ) Patients clinically significant medical condition include , limited cardiac , pulmonary , hepatic , hematological ( e.g . know coagulation disorder , history deep venous thrombosis and/or pulmonary embolism ) , endocrine , renal dysfunction , autoimmune disorder , severe environmental allergy chronic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>